ClinicalTrials.gg
CompletedNCT06794866Updated May 5, 2026

A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants

A Phase 3 interventional study of OnabotulinumtoxinA and Placebo in Forehead Lines, sponsored by AbbVie. Completed at 15 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Facial lines that develop from repeated facial expression, such as forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to assess adverse events and effectiveness of onabotulinumtoxinA in Japanese adults with moderate to severe FHL.

Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Participants are randomly assigned to receive onabotulinumtoxinA or placebo. There is a 1 in 5 chance that a participant will receive placebo. Around 150 adult participants with moderate to severe FHL will be enrolled in the study in approximately 15 sites in Japan.

In Period 1, participants will receive intramuscular injections on Day 1. In Period 2, participants will receive up to 3 additional treatment cycles. Participants will be followed for up to 12 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at the study site. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

02

Conditions studied

  • Forehead Lines

Keywords

  • Forehead Lines
  • OnabotulinumtoxinA
  • FHL Japan P3
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Forehead lines (FHL) of moderate or severe rating at maximum contraction as assessed by investigator using the Facial Wrinkle Scale with Asian Photonumeric Guide (FWS-A) at Day 1 prior to study treatment.
  • Glabellar lines (GL) of moderate or severe rating at maximum contraction as assessed by investigator using the FWS-A at Day 1 prior to study treatment.
  • Good health as per the investigator's judgment based on medical history, abbreviated physical examination and vital sign measurements, including no known active pandemic infection (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]).

Exclusion criteria

Exclusion Criteria:

  • FHL of severe rating at rest as assessed by investigator using the FWS-A at Day 1 prior to study treatment.
  • History of known immunization or to any botulinum neurotoxin serotype.
  • History of treatments to the mid or upper face.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants will receive onabotulinumtoxinA Dose A in both Period 1 and Period 2.

    Drug: OnabotulinumtoxinA

  • Experimental
    Group 2

    Participants will receive onabotulinumtoxinA Dose B in both Period 1 and Period 2.

    Drug: OnabotulinumtoxinA

  • Experimental
    Group 3

    Participants will receive placebo in Period 1 and onabotulinumtoxinA Dose A in Period 2.

    Drug: OnabotulinumtoxinA · Drug: Placebo

  • Experimental
    Group 4

    Participants will receive placebo in Period 1 and onabotulinumtoxinA Dose B in Period 2.

    Drug: OnabotulinumtoxinA · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve 'None' or 'Mild' on Facial Wrinkle Scale with Asian Photonumeric Guide (FWS-A) According to the Investigator Assessment of Forehead Lines (FHL) Severity at Maximum Contraction

    The investigator assesses FHL severity using the FWS-A scale ranging from none to severe.

    Time frame: Day 30

  2. Number of Participants with Adverse Events (AEs)

    Description: An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 12 months

Secondary outcomes

  1. Percentage of Participants who Achieved 'None' or 'Mild' on FWS-A According to the Participant Assessment of FHL Severity

    The participant assesses FHL severity using the FWS-A scale ranging from none to severe.

    Time frame: Day 30

  2. Percentage of Participants who Achieved at least 1-Grade Improvement from Baseline on FWS-A According to the Investigator Assessment of FHL Severity at Maximum Contraction

    The investigator assesses FHL severity using the FWS-A scale ranging from none to severe.

    Time frame: Day 30

  3. Percentage of Participants who Achieved at least 1-Grade Improvement from Baseline on FWS-A According to the Investigator Assessment of FHL Severity at Rest

    For participants rated as at least mild at baseline, the investigator assesses FHL severity using the FWS-A scale ranging from none to severe.

    Time frame: Day 30

  4. Time to Return to at least 'Moderate' for the Participants who Achieve Investigator FWS-A ratings of 'None' or 'Mild' on FHL Severity at Maximum Contraction

    The investigator assesses FHL severity using the FWS-A scale ranging from none to severe.

    Time frame: Day 30

  5. Percentage of Participants with Responder Status of 'Very Satisfied' or 'Mostly Satisfied' on Satisfaction with Treatment on the Facial Line Satisfaction Questionnaire (FLSQ)

    The FLSQ assesses treatment satisfaction and psychosocial impact. Participants assessed their satisfaction with FHL using the FLSQ scale ranging from Very dissatisfied to Very satisfied.

    Time frame: Day 60

  6. Percentage of Participants with Responder Status of 'Very Satisfied' or 'Mostly Satisfied' on Satisfaction with Natural Look on the FLSQ

    The FLSQ assesses treatment satisfaction and psychosocial impact. Participants assessed their satisfaction with FHL using the FLSQ scale ranging from Very dissatisfied to Very satisfied.

    Time frame: Day 30

  7. Change from Baseline in the Participant's Rasch-Transformed Score of the SKIN-Q Scale

    The SKIN-Q Scale is a scale that measures the appearance of skin quality response option ranging from Very dissatisfied to Very satisfied.

    Time frame: Day 30

  8. Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Social Function Scale at the Final Visit

    The FACE-Q Psychological Function is a scale that measures psychological function with options ranging from definitely disagree to definitely agree.

    Time frame: Day 30

07

Study locations

15 sites
  • Hiroshima Station Clinic /ID# 268467
    Hiroshima, Hiroshima 732-0053, Japan
  • Kotoni Tower Skin And Cosmetic Surgery Clinic /ID# 268460
    Sapporo, Hokkaido 063-0812, Japan
  • Tokai University Hospital /ID# 268496
    Isehara, Kanagawa 259-1193, Japan
  • Queens Square Medical Center, Dermatology and Allergology /ID# 268454
    Yokohama, Kanagawa 220-6208, Japan
  • Jun Clinic /ID# 268531
    Nagano, Nagano 380-0826, Japan
  • Touyama Plastic Surgery Clinic /ID# 268456
    Naha, Okinawa 900-0015, Japan
  • Yoshikawa Skin Clinic /ID# 268494
    Takatsuki, Osaka 569-0824, Japan
  • Tokyo Center Clinic /ID# 268477
    Chuo-ku, Tokyo 103-0027, Japan
  • Tokyo Asbo Clinic /ID# 268529
    Chuo-ku, Tokyo 104-0031, Japan
  • Ginza Skin Clinic /ID# 268532
    Chuo-ku, Tokyo 104-0061, Japan
  • Kitasato University Kitasato Institute Hospital /ID# 268499
    Minato-ku, Tokyo 108-8642, Japan
  • Forest Palace Dermatology Clinic /ID# 268599
    Nerima-ku, Tokyo 177-0041, Japan
  • Greenwood Skin Clinic Tachikawa /ID# 268528
    Tachikawa-shi, Tokyo 190-0023, Japan
  • Chiharu Dermatology Clinic Urawa /ID# 268497
    Saitama, 333-0055, Japan
  • Akihabara Skin Clinic /ID# 268441
    Tokyo, 101-0021, Japan
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Apr 2026, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2025
First posted
Jan 27, 2025
StartActual
Jan 22, 2025
Primary completionActual
Apr 3, 2026
CompletionActual
Apr 3, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06794866
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Jan 22, 2025
Primary completion
Apr 3, 2026
Completion
Apr 3, 2026
Last update
May 5, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion